A Rapid Metabolomic Test for Early Diagnosis of Myocardial Infarction
|
By LabMedica International staff writers Posted on 03 May 2021 |
|
Image: A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle (Photo courtesy of Wikimedia Commons)
A metabolomic platform with GC/MS (gas chromatography–mass spectrometry) and LC/MS (liquid chromatography–mass spectrometry) instrumentation has been developed to profile plasma metabolites of patients with chest pain for early detection of myocardial infarction (MI).
Investigators at Nanjing Medical University (People’s Republic of China) were working to develop a simple blood test to aid clinicians in diagnosing a heart attack with a rapid, noninvasive assay method.
To this end, they analyzed plasma metabolites in MI and non-MI chest pain cases to identify markers for diagnosis of MI based on metabolomics. Non-MI cardiac chest pain cases included unstable angina (UA), myocarditis, and valvular heart diseases. A total of 230 volunteers were recruited, consisting of 146 chest pain patients admitted with suspected MI (85 MIs and 61 non-MI chest pain cases) and 84 control individuals. Blood samples from all suspected MI cases were collected not longer than six hours after the onset of chest pain. Gas chromatography–mass spectrometry and liquid chromatography–mass spectrometry were applied to identify and quantify the plasma metabolites.
Results revealed that metabolites belonging to pyrimidine, methionine, and arginine metabolism were elevated in MI plasma samples. Specifically, deoxyuridine (dU), homoserine, and methionine were identified as potential markers for distinguishing MI cases from other cardiac chest pain cases after the onset of chest pains. Individuals with high plasma abundance of dU, homoserine, or methionine were also found to have increased risk of MI.
"We analyzed circulating metabolites in blood plasma samples from cardiac chest pain patients, including heart attack cases and other cardiac chest pain cases, to identify potential markers for heart attack diagnosis and early warning," said contributing author Dr. Xiangqing Kong, a senior researcher at Nanjing Medical University. "Such markers could be helpful in confirming heart attack in a timely manner when angiography is unavailable."
The identification of metabolites useful for early diagnosis of MI was described in the April 23, 2021, online edition of the journal Frontiers in Cardiovascular Medicine.
Related Links:
Nanjing Medical University
Investigators at Nanjing Medical University (People’s Republic of China) were working to develop a simple blood test to aid clinicians in diagnosing a heart attack with a rapid, noninvasive assay method.
To this end, they analyzed plasma metabolites in MI and non-MI chest pain cases to identify markers for diagnosis of MI based on metabolomics. Non-MI cardiac chest pain cases included unstable angina (UA), myocarditis, and valvular heart diseases. A total of 230 volunteers were recruited, consisting of 146 chest pain patients admitted with suspected MI (85 MIs and 61 non-MI chest pain cases) and 84 control individuals. Blood samples from all suspected MI cases were collected not longer than six hours after the onset of chest pain. Gas chromatography–mass spectrometry and liquid chromatography–mass spectrometry were applied to identify and quantify the plasma metabolites.
Results revealed that metabolites belonging to pyrimidine, methionine, and arginine metabolism were elevated in MI plasma samples. Specifically, deoxyuridine (dU), homoserine, and methionine were identified as potential markers for distinguishing MI cases from other cardiac chest pain cases after the onset of chest pains. Individuals with high plasma abundance of dU, homoserine, or methionine were also found to have increased risk of MI.
"We analyzed circulating metabolites in blood plasma samples from cardiac chest pain patients, including heart attack cases and other cardiac chest pain cases, to identify potential markers for heart attack diagnosis and early warning," said contributing author Dr. Xiangqing Kong, a senior researcher at Nanjing Medical University. "Such markers could be helpful in confirming heart attack in a timely manner when angiography is unavailable."
The identification of metabolites useful for early diagnosis of MI was described in the April 23, 2021, online edition of the journal Frontiers in Cardiovascular Medicine.
Related Links:
Nanjing Medical University
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automatic CLIA Analyzer
Shine i6000
POC Immunoassay Analyzer
Procise DX
Latest Molecular Diagnostics News
- Expanded Sequencing Panel Supports Myeloid Malignancy Variant Profiling
- Tumor Markers Help Predict Response to Less Intensive HER2+ Chemotherapy
- New Molecular Testing Support to Strengthen Ebola Surveillance in DRC
- Functional Testing From Skin Biopsy Improves Detection of Mitochondrial Disease
- Blood Test Detects Molecular Signals of Early Liver Cancer Progression
- Breast Milk DNA Test Investigated for Early Breast Cancer Detection
- Blood-Based MRD Test Shows High Specificity in Colorectal Cancer Trials
- Blood-Based MRD Test Predicts Recurrence Risk After Melanoma Surgery
- Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
- Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis
- Facilitated Cascade Program Increases Genetic Testing in Hereditary Cancer Families
- Bile DNA Testing Detects Tumor Signals Before Conventional Cancer Diagnosis
- Blood-Based Test Broadens Colorectal Cancer Screening Options
- New Blood Test Could Help Predict Severe Scoliosis in Adolescents
- Single Assay Enables Simultaneous Newborn Screening for Three Severe Genetic Disorders
- Genetic Testing Identifies Inherited Predisposition in Children With Acute Leukemia
Channels
Clinical Chemistry
view channel
Lollipop-Inspired Device Measures Acetaminophen Levels in Saliva
Acetaminophen is used in many over-the-counter pain relievers, cold and flu products, and other medications. Excess dosing can cause serious side effects, including liver damage, and children may be at... Read more
New Insights Into Fetal DNA Could Improve Non-Invasive Prenatal Testing
Non-invasive prenatal testing is widely used to screen pregnancies for genetic conditions by analyzing DNA fragments in maternal blood. Although it offers a safer alternative to invasive procedures such... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
New Web-Based Platform Helps Autoimmune Laboratories Manage Testing Complexity
Autoimmune disease testing often requires laboratories to coordinate results across multiple instruments, manual microscopy, and patient histories. As testing volumes and workflow complexity increase,... Read more
Routine Newborn Blood Spots Can Measure GBS Antibody Levels
Group B Streptococcus (GBS) can cause serious infections in newborns. Protecting infants remains challenging because immune protection may depend on antibodies transferred from mother to baby before birth.... Read more
Microbiology
view channel
Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more
Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read morePathology
view channel
Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
CellCarta (Montreal, Canada) and Imagene AI (Miami, FL, USA) have expanded their collaboration to provide biopharma companies with a coordinated pathway for biomarker strategy, assay development, validation,... Read more
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more